60d FRN - published

36552

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices

in Phase I but who failed to fill their
ARV prescriptions in the subsequent 30
days of the Phase I consultation, and for
participants who are >60 to <90 days
late at the time the participant was
determined to be study eligible. In
Phase II, the Linkage Coordinator will
lead a similar consultation as in Phase
I, but will probe for more complex
adherence barriers (e.g., mental health
concerns) and referrals will be made
accordingly. The participant will also be
offered an evidence-informed mobile
application (‘‘app’’) which is designed
to support ART adherence and retention
in care.
The provider-level intervention will
consist of a peer-to-peer clinician
consultation delivered by clinicians
from the Virginia Department of
Health’s Advisory Committee to the
Virginia Medication Assistance Program
or by another HIV clinical expert. The

intervention and 40 participants of the
provider-level intervention) and 500
controls over the three-year project
period. Secondary data will be
abstracted from the Virginia Medicaid
and Virginia Care Markers databases to
determine study eligibility, to conduct
the patient- and provider-level
interventions, and to determine study
outcomes. During the patient-level
intervention, data will be collected on
participants’ adherence barriers; this
information will be used to refer
participants to appropriate resources to
assist their adherence to ART. During
the provider-level intervention data will
be collected to inform the peer-to-peer
clinician consultation.
CDC requests OMB approval for an
estimated 687 burden hours annually.
There are no costs to respondents other
than their time to participate.

peer-to-peer clinician consultations will
involve introduction or reinforcement of
HIV clinical guidelines for ART
initiation, strategies to optimize ART
adherence, and resources for supporting
adherence for people with HIV. The
consultation will be tailored to the
needs of the provider participant.
All analyses will be conducted at the
patient level. Persons within the
intervention arm will be followed
prospectively for 12 months. At the end
of the intervention arm follow-up
period, persons within the usual care
arm will be followed retrospectively for
12 months. The primary study outcome
of HIV viral suppression (HIV RNA
<200 copies/mL) will be compared
between study arms.
CDC requests OMB approval to collect
standardized information from 500
AIMS study participants (460
participants of the patient-level

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Average
burden per
response
(in hours)

Total burden
hours

Form name

Participants .......................................
Provider participants .........................

Verbal consent—participants ...........
Verbal consent—provider participants.
Verbal consent—control participants
(for participants of provider-level
intervention).
Verbal consent—control participants
PositiveLinks enrollment ..................
Phase I interview ..............................
Phase II interview .............................
Clinician consultation .......................

460
40

1
1

15/60
15/60

115
10

40

1

15/60

10

500
100
460
100
10

1
1
1
1
4

15/60
60/60
30/60
30/60
30/60

125
100
230
50
20

Clinician consultation .......................
Post-consultation questionnaire .......

40
10

1
4

30/60
10/60

20
7

...........................................................

........................

........................

........................

687

Participants .......................................
Control participants ...........................
PositiveLinks participants ..................
Participants .......................................
Participants .......................................
Advisory Committee to the Virginia
Medication Assistance Program
member and other HIV clinical expects.
Provider participants .........................
Advisory Committee to the Virginia
Medication Assistance Program
member and other HIV clinical expects.
Total ...........................................

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–14752 Filed 7–9–21; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

BILLING CODE 4163–18–P

[60 Day–21–0530; Docket No. CDC–2021–
0064]
khammond on DSKJM1Z7X2PROD with NOTICES

Number of
responses per
respondent

Type of respondent

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

PO 00000

Frm 00031

Fmt 4703

Sfmt 4703

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Energy Employees Occupational
Illness Compensation Program Act
(EEOICPA) Dose Reconstruction
Interviews and Forms. This data
collection permits claimants under

SUMMARY:

E:\FR\FM\12JYN1.SGM

12JYN1

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
EEOICPA to provide information
potentially useful in reconstructing
radiation doses, and to confirm that they
have no further information to submit.
DATES: CDC must receive written
comments on or before September 10,
2021.
You may submit comments,
identified by Docket No. CDC–2021–
0064 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including

khammond on DSKJM1Z7X2PROD with NOTICES

ADDRESSES:

VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Energy Employees Occupational
Illness Compensation Program Act
(EEOICPA) Dose Reconstruction
Interviews and Forms (OMB Control No.
0920–0530, Exp. 1/31/2022)—
Revision—National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
On October 30, 2000, the Energy
Employees Occupational Illness
Compensation Program Act of 2000 (42
U.S.C. 7384–7385) was enacted. This
Act established a federal compensation
program for employees of the
Department of Energy (DOE) and certain
of its contractors, subcontractors and
vendors, who have suffered cancers and
other designated illnesses as a result of
exposures sustained in the production
and testing of nuclear weapons.
Executive Order 13179, issued on
December 7, 2000, delegated authorities
assigned to ‘‘the President’’ under the
Act to the Departments of Labor, Health
and Human Services, Energy and
Justice. The Department of Health and
Human Services (DHHS) was delegated
the responsibility of establishing
methods for estimating radiation doses
received by eligible claimants with
cancer applying for compensation.
NIOSH is applying the following
methods to estimate the radiation doses
of individuals applying for
compensation.
In performance of its dose
reconstruction responsibilities, under
the Act, NIOSH is providing voluntary
interview opportunities to claimants (or
their survivors) individually, and

PO 00000

Frm 00032

Fmt 4703

Sfmt 4703

36553

providing them with the opportunity to
assist NIOSH in documenting the work
history of the employee by
characterizing the actual work tasks
performed. In addition, NIOSH and the
claimant may identify incidents that
may have resulted in undocumented
radiation exposures, characterize
radiological protection and monitoring
practices, and identify co-workers and
other witnesses, as may be necessary, to
confirm undocumented information. In
this process, NIOSH uses a computer
assisted telephone interview (CATI)
system, which allows interviews to be
conducted more efficiently and quickly
as opposed to a paper-based interview
instrument. Both interviews are
voluntary, and failure to participate in
either or both interviews will not have
a negative effect on the claim, although
voluntary participation may assist the
claimant by adding important
information that may not be otherwise
available.
NIOSH uses the data collected in this
process to complete an individual dose
reconstruction that accounts, as fully as
possible, for the radiation dose incurred
by the employee in the line of duty for
DOE nuclear weapons production
programs. After dose reconstruction,
NIOSH also performs a brief, voluntary
final interview with the claimant to
explain the results and to allow the
claimant to confirm or question the
records NIOSH has compiled. This will
also be the final opportunity for the
claimant to supplement the dose
reconstruction record.
At the conclusion of the dose
reconstruction process, the claimant
submits a form to confirm that the
claimant has no further information to
provide to NIOSH about the claim at
this time. The form notifies the claimant
that signing the form allows NIOSH to
forward a dose reconstruction report to
DOL and to the claimant, and closes the
record on data used for the dose
reconstruction. Signing this form does
not indicate that the claimant agrees
with the outcome of the dose
reconstruction. The dose reconstruction
results will be supplied to the claimant
and to the DOL, the agency that will
utilize them as one part of its
determination of whether the claimant
is eligible for compensation under the
Act.
CDC requests approval for an
estimated 3,900 burden hours annually.
There is no cost to respondents other
than their time.

E:\FR\FM\12JYN1.SGM

12JYN1

36554

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Total
burden
(in hours)

Claimant .........................
Claimant .........................

Initial Interview .....................................................
Conclusion Form OCAS–1 ..................................

3,600
3,600

1
1

1
5/60

3,600
300

Total ........................

..............................................................................

........................

........................

........................

3,900

[FR Doc. 2021–14753 Filed 7–9–21; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH), National
Institute for Occupational Safety and
Health (NIOSH)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).

AGENCY:

Notice of meeting and request
for comment.

ACTION:

In accordance with the
Federal Advisory Committee Act, the
CDC, announces the following meeting
of the Advisory Board on Radiation and
Worker Health (ABRWH or the Advisory
Board). This meeting is open to the
public, limited only by the space
available. The are 200 spaces for the
audio conference and computer lines
combined. The public is welcome to
submit written comments in advance of
the meeting, to the contact person
below. Written comments received in
advance of the meeting will be included
in the official record of the meeting. The
public is also welcomed to listen to the
meeting by joining a teleconference line
and/or computer connection
(information below).

SUMMARY:

The meeting will be held on
August 18, 2021, from 1:00 p.m. to 6:30
p.m., EDT, and August 19, 2021, from
1:00 p.m. to 4:15 p.m., EDT. A public
comment session will be held on August
18, 2021 at 5:30 p.m. and will conclude
at 6:30 p.m., EDT or following the final
call for public comment, whichever
comes first. Written comments must be
received on or before August 11, 2021.

DATES:

VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

Number of
respondents

Average
burden per
response
(in hours)

Form name

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.

khammond on DSKJM1Z7X2PROD with NOTICES

Number of
responses per
respondent

Type of
respondents

You may submit comments
by mail to: Sherri Diana, National
Institute for Occupational Safety and
Health, 1090 Tusculum Avenue, MS C–
34, Cincinnati, Ohio 45226. Meeting
Information: The USA toll-free dial-in
numbers are: +1 669 254 5252 US (San
Jose); +1 646 828 7666 US (New York);
+1 551 285 1373 US; +1 669 216 1590
US (San Jose); The Meeting ID is: 161
786 4323 and the Passcode is: 76650371;
Web conference by Zoom meeting
connection: https://cdc.zoomgov.com/j/
1617864323?pwd=NWFzTmNlbU
tmOFFmMlNlbmZ0WUczZz09.
FOR FURTHER INFORMATION CONTACT:
Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090
Tusculum Avenue, Mailstop C–24,
Cincinnati, Ohio 45226; Telephone:
(513) 533–6800; Toll Free: 1 (800) CDC–
INFO; email: [email protected].
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines
which have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule, advice on
methods of dose reconstruction which
have also been promulgated by HHS as
a final rule, advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program, and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC). In
December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS,
which subsequently delegated this
authority to the CDC. NIOSH
implements this responsibility for CDC.
The Advisory Board’s charter was
issued on August 3, 2001, renewed at
ADDRESSES:

PO 00000

Frm 00033

Fmt 4703

Sfmt 4703

appropriate intervals, rechartered on
March 22, 2020, and will terminate on
March 22, 2022.
Purpose: This Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advising the Secretary
on whether there is a class of employees
at any Department of Energy facility
who were exposed to radiation but for
whom it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
Matters To Be Considered: The agenda
will include discussions on the
following: NIOSH Program Update;
Department of Labor Program Update;
Department of Energy Program Update;
SEC Petitions Update; Procedures
Review Finalization/Document
Approvals; Oak Ridge National
Laboratory (X–10), Y–12 SEC Petition
#250 Addendum Update (Oak Ridge,
Tennessee; 1987–1994), and a Board
Work Session. Agenda items are subject
to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–14685 Filed 7–9–21; 8:45 am]
BILLING CODE 4163–18–P

E:\FR\FM\12JYN1.SGM

12JYN1